Showing papers in "Blood in 2002"
••
TL;DR: The data demonstrate that autologous or allogeneic BMSCs strongly suppress T-lymphocyte proliferation, this phenomenon that is triggered by both cellular as well as nonspecific mitogenic stimuli has no immunologic restriction, and T-cell inhibition is not due to induction of apoptosis and is likely due to the production of soluble factors.
3,127 citations
••
TL;DR: The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.
2,155 citations
••
TL;DR: This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.
2,000 citations
••
TL;DR: Possibility for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed, as cancer patients with venous thrombosis are more likely to develop recurrent thromboembolic complications and major bleeding during anticoaggerant treatment than those without malignancy.
1,655 citations
••
TL;DR: In this paper, the authors analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 acute myelogenous leukemia (AML) patients and found that a high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance.
1,615 citations
••
TL;DR: In this paper, the prognostic impact of cytogenetic abnormalities on complete remission (CR) rate, 5-year cumulative incidence of relapse (CIR), and 5-to-5-year overall survival (OS) of acute myeloid leukemia (AML) patients was investigated.
1,559 citations
••
TL;DR: Results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene, and preliminary studies suggest that mutantFLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype.
1,454 citations
••
TL;DR: It is suggested that multiple immunological dysfunctions, including cytokine production capability, in addition to functional incompetence of T, B, and NK cells, may lead to the high engraftment levels of xenograft in NOD/SCID/gamma(c)(null) mice.
1,382 citations
••
TL;DR: In vitro insensitivity to STI571, in combination with its demonstrated antiproliferative activity, could translate into disease relapse after prolonged therapy despite dramatic short-term responses in vivo.
1,219 citations
••
TL;DR: It is demonstrated that imatinib has substantial activity and a favorable safety profile when used as a single agent in patients with CML in blast crisis and additional clinical studies are warranted to explore the efficacy and feasibility of imatinIB used in combination with other antileukemic drugs.
1,172 citations
••
TL;DR: This study is the first to demonstrate that activated, cultured CD4(+)CD25(+) cells can offer substantial protection in a relevant in vivo animal model of disease and have important ramifications for clinical bone marrow and solid organ transplantation.
••
TL;DR: The results indicate that all of the effects of CSF-1 are mediated via the CSf-1R, but that subtle effects of the CS fms proto-oncogene could result from its CS F-1-independent activation.
••
TL;DR: Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase, and a daily dose of 600 mg is more effective than 400 mg, with similar toxicity.
••
TL;DR: Changes in ferritin are important not only in the classic diseases of iron acquisition, transport, and storage, but also in diseases such as primary hemochromatosis.
••
TL;DR: There is a high probability of survival in recipients of UCB grafts that are disparate in no more than 2 human leukocyte antigens when the grafts contain at least 1.7 x 10(5) CD34(+) cells per kilogram of recipient's body weight, and graft selection should be based principally on CD34 cell dose when multiple UCB units exist with an HLA disparity of 2 or less.
••
TL;DR: Alemtuzumab induced significant responses in patients with relapsed or refractory B-cell chronic lymphocytic leukemia with clinical benefit in the majority and with acceptable toxicity in a high-risk group.
••
TL;DR: The most frequent mutation in acute myeloid leukemia (AML) is the FLT3 length mutation (FLT3-LM) as discussed by the authors, which is a molecular marker potentially useful for the characterization of AML.
••
TL;DR: Risk factor analyses verify previously recognized risk factors (GVHD, receipt of corticosteroids, and neutropenia) and uncover the roles of lymphopenia and viral infections in increasing the incidence of postengraftment IA in the 1990s.
••
TL;DR: In this article, pre-treatment samples from 224 patients with acute myeloid leukemia (AML) and normal cytogenetics were analyzed for FLT3 internal tandem duplications (ITDs) and Asp835 mutations.
••
TL;DR: In multivariate analysis, unmutated V(H), 17p deletion, 11q deletion, age, WBC, and LDH were identified as independent prognostic factors, indicating a complementary role of V (H) mutation status and genomic aberrations to predict outcome in CLL.
••
TL;DR: This study provides the basis for the evaluation of CC-5013, either alone or in combination, to treat patients with MM at earlier stages of disease and shows no significant somnolence, constipation, or neuropathy has been seen in any cohort.
••
TL;DR: Results suggest that cleavage of EC-derived ULVWF multimers by ADAMTS-13 is a rapid physiologic process that occurs on endothelial cell surfaces.
••
TL;DR: Comparison of messenger RNA levels for the 3 major multidrug-resistant efflux pumps, MDR1, MRP1, and ABCG2, in bone marrow SP cells reveals that ABCG 2 is the predominant form in these cells.
••
TL;DR: The poor viability of CD123(-) DCs in vitro was confirmed, but the CD16(+) CD11c(+) DC subset also survived poorly, and these data provide an opportunity to standardize the DC populations used for future molecular, functional and possibly even therapeutic studies.
••
TL;DR: HLH-94 is very effective, allowing BMT in most patients, and survival of children with HLH has been greatly improved.
••
TL;DR: Anti-CMV cellular therapy was successful in 5 of 7 patients, whereas in 2 of7 patients, who received an intensified immune suppression at the time of or after T-cell therapy, only transient reductions in virus load were obtained.
••
TL;DR: A high frequency of mutations clustered within the ATP-binding region of BCR/ABL in resistant patients is confirmed and may allow intervention before relapse by identifying emerging mutations with defined impacts on imatinib binding.
••
TL;DR: The mechanism of action of IMiDs against MM cells in vitro is delineated and form the basis for clinical trials of these agents, alone and coupled with conventional and other novel therapies, to improve outcome in MM.
••
TL;DR: Novel candidate MM disease genes have been identified using gene expression profiling and this profiling has led to the development of a gene-based classification system for MM.
••
TL;DR: CD38 expression is an independent risk factor that can be used with IgV(H) mutations and clinical stage to select patients with B-CLL with the worst prognoses.